Novamind's CEO, Yaron Conforti, on the Green Rush Podcast
Anne and Nick sat down with Yaron to chat with him about the more than 4,000 ketamine-assisted psychotherapy treatments Novamind has administered.
Novamind CEO On Going Public: 'We're Focused On Treating People Today'
Novamind became the latest psychedelics company to go public through a reverse take-over with Hinterland Metals Inc.
Business Insider Review of Novamind's Investor Deck
See the 20-slide pitch deck Novamind used to raise funds to build out a network of ketamine clinics.
Novamind's Chief Medical Officer and Chief Executive Officer Interview with Cheddar News
Discussed Novamind’s recent listing on the Canadian Securities Exchange.
Novamind on State of the Psychedelic Medicine Industry and Focus on Building the Infrastructure
SNNLive spoke with Yaron Conforti, CEO of Novamind Inc.
Novamind CEO Shares His Thoughts on Psychedelics, Policy, and Healing
Psytech interviewed Novamind's CEO to discuss his thoughts on psychedelics, policy, and healing.